Merck Bets on AI & Human Antibodies in $838M Infinimmune Pact

ALAMEDA, Calif. – March 31, 2026 – In a significant endorsement of next-generation drug discovery, pharmaceutical giant Merck has entered into a major collaboration with biotech innovator Infinimmune. The deal, potentially worth up to $838 million, will leverage Infinimmune’s unique artificial intelligence and human-derived antibody platform to develop new therapeutics against multiple undisclosed targets.

The partnership grants Merck exclusive rights to develop and commercialize any antibody candidates that emerge from the collaboration. For Infinimmune, a young company that has raised just $22 million in venture capital since its 2022 launch, the agreement provides a substantial financial runway and powerful validation of its novel approach to creating medicine.

A 'Human-First' Revolution in Drug Discovery

At the heart of the collaboration is Infinimmune's proprietary technology, which combines direct insights from the human immune system with the predictive power of advanced AI. This “human-first” methodology seeks to overcome the limitations of traditional antibody discovery, which often relies on animal models or synthetic libraries that can lead to candidates that are ineffective or trigger adverse immune reactions in patients.

Infinimmune’s process begins with its Anthrobody® platform, which screens millions of individual memory B cells sourced from a diverse population of human donors. By tapping directly into the human immune repertoire, the company identifies fully human, natively paired antibodies that have already been vetted and optimized by the body’s own sophisticated machinery. This approach is designed to yield candidates with inherently stronger affinity, specificity, and more favorable drug-like properties from the outset.

These vast biological datasets then power the company's GLIMPSE™ antibody language model. Unlike generative AI models trained on broad protein databases, GLIMPSE™ was trained exclusively on Infinimmune’s massive library of naturally occurring human antibody sequences. This allows the AI to “speak the language” of the human immune system, enabling it to rapidly optimize candidates for potency and manufacturability, and even engineer novel variants—all performed in silico before costly and time-consuming lab experiments begin.

“By discovering antibodies directly from human immune systems and combining that biology with advanced AI-driven engineering, we can uncover therapeutic opportunities that traditional discovery approaches may not access,” said Wyatt McDonnell, Ph.D., CEO and co-founder of Infinimmune. “This collaboration allows us to scale our human-first discovery engine and accelerate the development of differentiated biologics.”

Merck's Strategic Pivot to AI and External Innovation

The partnership is a clear indicator of Merck's broader R&D strategy. Facing looming patent expirations on blockbuster drugs, the pharmaceutical titan is aggressively pursuing external innovation and cutting-edge technologies like AI to restock its pipeline and enhance R&D productivity.

This deal is the latest in a series of similar agreements for Merck. The company has recently announced partnerships with AI-driven firms like BenevolentAI and Exscientia for small molecule discovery, BiolojicDesign for multi-specific antibodies, and a multi-billion dollar pact with Quotient Therapeutics to identify new disease targets. These moves signal a strategic shift toward leveraging specialized, data-driven platforms to gain a competitive edge.

Infinimmune's platform appears to fit perfectly within this strategy, offering a novel way to de-risk and accelerate the notoriously difficult process of biologics discovery. By starting with antibodies derived from humans, Merck can potentially increase the probability of clinical success and reduce development timelines.

“At Merck, we are committed to advancing innovative approaches that improve the speed and rigor of drug discovery,” noted Juan Alvarez, Ph.D., Vice President of Biologics Discovery at Merck Research Laboratories. “Infinimmune’s platform enables the discovery of antibodies directly from the human immune system, offering a compelling new way to access novel biology and promising therapeutic candidates.”

Navigating a Competitive AI-Driven Landscape

Infinimmune and Merck are entering a field that is both promising and increasingly crowded. The race to apply AI to drug discovery has attracted billions in investment, with numerous companies like Generate:Biomedicines and Xaira Therapeutics pioneering de novo design of antibodies using generative AI. Other competitors, such as Nona Biosciences, are also integrating AI with their own discovery platforms.

However, Infinimmune’s strict focus on learning from and optimizing existing human antibodies, rather than designing them entirely from scratch, serves as a key differentiator. The company is betting that the most effective and safest drugs are those that closely mimic the solutions already perfected by human evolution.

While the industry is abuzz with the potential of AI, the ultimate validation remains pending, as no AI-designed antibody has yet secured regulatory approval. This collaboration, however, represents a significant step in that direction, pairing a promising technology with the clinical development and commercialization power of a global pharmaceutical leader.

Beyond its partnership with Merck, Infinimmune is also advancing its own internal pipeline of antibodies for inflammatory and immunological diseases. Programs include IFX-101, an IL-22 inhibitor, and IFX-201, an IL-13 inhibitor, both being developed for moderate-to-severe atopic dermatitis, demonstrating the company's commitment to proving out its platform by developing its own assets.